tiprankstipranks
Trending News
More News >
MedCap AB (SE:MCAP)
:MCAP
Advertisement

MedCap AB (MCAP) AI Stock Analysis

Compare
0 Followers

Top Page

SE:MCAP

MedCap AB

(Frankfurt:MCAP)

Rating:68Neutral
Price Target:
kr671.00
▲(8.93%Upside)
MedCap AB's strong financial performance supports its stock score, driven by robust revenue growth and profitability. However, technical analysis suggests potential short-term volatility due to overbought conditions, and the high P/E ratio raises concerns about valuation. These factors collectively result in a moderate overall stock score.

MedCap AB (MCAP) vs. iShares MSCI Sweden ETF (EWD)

MedCap AB Business Overview & Revenue Model

Company DescriptionMedCap AB (MCAP) is a Sweden-based investment company that focuses on acquiring and developing small to medium-sized enterprises (SMEs) within the healthcare sector. The company's investment portfolio spans across various segments of the healthcare industry, including pharmaceuticals, medical devices, and healthcare services. MedCap aims to create long-term value by leveraging its industry expertise to drive growth and improve operational efficiencies within its portfolio companies.
How the Company Makes MoneyMedCap AB makes money primarily through the strategic acquisition and management of healthcare-related companies. The company generates revenue through the operational profits of its portfolio companies, which encompass a diverse range of healthcare sectors such as pharmaceuticals, medical devices, and healthcare services. MedCap enhances the value of its investments by working closely with the management of its portfolio companies to boost their market presence, streamline operations, and foster innovation. Additionally, MedCap may realize earnings through the eventual sale or public offering of its portfolio companies, thereby capitalizing on the increased value created through its strategic guidance and industry expertise. Significant partnerships with other healthcare organizations and stakeholders also play a role in enhancing the performance and profitability of its investments.

MedCap AB Financial Statement Overview

Summary
MedCap AB exhibits strong financial health with impressive revenue growth, solid profitability margins, and effective cash flow management. The company maintains a conservative balance sheet with low leverage and strong equity financing. However, potential cost pressures and liquidity concerns warrant attention.
Income Statement
85
Very Positive
MedCap AB has demonstrated robust revenue growth, with a consistent increase in total revenue over the years. The TTM period shows a gross profit margin of 47.1% suggesting strong control over cost of goods sold. The net profit margin for the TTM is 11.0%, indicating healthy profitability. The EBIT and EBITDA margins of 13.9% and 20.7%, respectively, highlight efficient operational management. However, a slight decline in EBIT and EBITDA margins compared to the previous annual period points to potential cost pressures.
Balance Sheet
78
Positive
The company's balance sheet reflects a solid financial position with a debt-to-equity ratio of 0.27 during the TTM, signifying low leverage. The return on equity for TTM stands at 15.4%, showcasing effective use of shareholder funds to generate profit. The equity ratio of 64.3% indicates a stable capital structure with significant equity financing. However, the decreasing trend in cash and cash equivalents may warrant attention for liquidity management.
Cash Flow
82
Very Positive
MedCap AB has shown a positive operating cash flow to net income ratio of 1.60 for TTM, indicating strong cash generation relative to its net income. The free cash flow to net income ratio is 1.29, reflecting efficient capital expenditure management. Despite a decline in free cash flow growth rate, the company maintains a healthy cash flow position supporting its operations and future investments.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.84B1.81B1.59B1.11B916.30M817.40M
Gross Profit865.60M1.06B926.40M462.40M369.80M326.60M
EBITDA381.50M396.00M327.40M237.30M186.80M147.80M
Net Income201.70M207.40M172.20M117.60M96.50M60.90M
Balance Sheet
Total Assets2.03B1.99B1.66B1.43B1.17B1.08B
Cash, Cash Equivalents and Short-Term Investments315.20M370.10M188.20M236.20M139.70M146.50M
Total Debt347.30M358.00M261.20M340.00M256.90M263.70M
Total Liabilities721.00M703.20M635.10M570.60M471.80M479.30M
Stockholders Equity1.31B1.28B1.02B856.30M696.00M595.70M
Cash Flow
Free Cash Flow260.90M293.80M188.70M41.20M55.40M91.20M
Operating Cash Flow323.10M360.00M228.00M85.50M116.30M115.60M
Investing Cash Flow-171.10M-128.80M-152.30M-56.10M-64.80M-131.90M
Financing Cash Flow-57.40M-46.10M-119.70M61.20M-64.10M144.50M

MedCap AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price616.00
Price Trends
50DMA
462.55
Positive
100DMA
422.04
Positive
200DMA
467.38
Positive
Market Momentum
MACD
30.84
Negative
RSI
83.10
Negative
STOCH
66.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MCAP, the sentiment is Positive. The current price of 616 is above the 20-day moving average (MA) of 507.27, above the 50-day MA of 462.55, and above the 200-day MA of 467.38, indicating a bullish trend. The MACD of 30.84 indicates Negative momentum. The RSI at 83.10 is Negative, neither overbought nor oversold. The STOCH value of 66.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:MCAP.

MedCap AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
kr9.48B48.8815.85%9.32%-7.55%
64
Neutral
kr5.90B13.31-3.12%3.00%
64
Neutral
€22.27B189.450.27%0.92%13.61%-97.82%
63
Neutral
kr4.28B105.957.13%0.27%2.42%20.90%
57
Neutral
€4.62B17.85-10.05%37.32%-39.07%
52
Neutral
kr5.63B10.38-63.86%1.96%27.11%26.73%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:MCAP
MedCap AB
651.00
60.00
10.15%
SE:BURE
Bure Equity AB
299.80
-95.92
-24.24%
SE:IDUN.B
Idun Industrier AB Class B
369.00
101.73
38.06%
SE:LINC
Linc AB
79.70
-21.10
-20.93%
SE:SVOL.B
Svolder AB Class B
56.60
-4.73
-7.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025